Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Pralsetinib therapy shows high response in range of cancer patients with RET gene fusions

Written by | 20 Aug 2022

In a Phase I/II trial, cancer treatment with pralsetinib has produced high response rates in patients with RET gene fusions, regardless of tumor type, researchers reported on Aug.12,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.